E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 20
- Registration Number
- NCT05686226
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธRWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1
Not yet recruiting
- Conditions
- Oropharynx CancerHPV-Associated Cervical CarcinomaHPV-Related CarcinomaHPV-Related MalignancyHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related AdenocarcinomaHPV-Related Adenosquamous CarcinomaHPV-Related Squamous Cell CarcinomaHPV-Related Penile Squamous Cell CarcinomaHPV-Related Endocervical Adenocarcinoma
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 15
- Registration Number
- NCT05639972
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธRWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Christian Hinrichs
- Target Recruit Count
- 30
- Registration Number
- NCT05483491
- Locations
- ๐บ๐ธ
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
๐บ๐ธRWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath